Literature DB >> 26614849

The frequency of pulmonary hypertension in patients with juvenile scleroderma.

Amra Adrovic1, Funda Oztunc, Kenan Barut, Aida Koka, Refet Gojak, Sezgin Sahin, Tuncalp Demir, Ozgur Kasapcopur.   

Abstract

Juvenile scleroderma (JS) represents a rarely seen group of connective tissue diseases with multiple organ involvement. Cardiac involvement in JSS is well known and, although rare in children, it may be an important cause of mortality and morbidity. Therefore, an early determination of cardio-vascular and pulmonary involvement is of the most relevance to reduce the mortality in patients with juvenile scleroderma. The aim of the study was to explore the non-invasive methods (Doppler echocardiography, pulmonary function tests), Forced vital capacity (FVC) and Carbon monoxide diffusion capacity (DLCO) in the assessment of the cardiopulmonary involvement in patients with JS. The assessment of pulmonary arterial pressure (PAP) and risk factors for pulmonary arterial hypertension (PAH) were made by the measurement of maximum tricuspid insufficiency (TI), end-diastolic pulmonary insufficiency (PI), ratio of acceleration time (AT) to ejection time (ET) (AT/ET), right atrial pressure (RAP) and contraction of vena cava inferior during inspiration. Thirty-five patients with confirmed JS were included in the study. The mean age of onset of the disease was 9.57 years (median 10 years, range 2-18 years). The mean disease duration and follow-up time was 2 years (median 1 year, range 0.5-8 years) and 3.57 years (median 2 years, range 0.5-14.5 years), respectively.The values of all the analyzed parameters including TI, PI, AT/ET, PAP, FVC and DLCO were found to be within normal ranges in all the patients tested, confirming an uncommonness of cardiopulmonary involvement in patients with juvenile scleroderma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26614849      PMCID: PMC4690439          DOI: 10.17305/bjbms.2015.596

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  21 in total

Review 1.  Connective tissue associated pulmonary arterial hypertension.

Authors:  J G Coghlan; C Handler
Journal:  Lupus       Date:  2006       Impact factor: 2.911

2.  Noninvasive assessment of pulmonary artery pressures: moving beyond tricuspid regurgitation velocities.

Authors:  Sheldon E Litwin
Journal:  Circ Cardiovasc Imaging       Date:  2010-03       Impact factor: 7.792

Review 3.  Diagnosis and management of pulmonary hypertension in systemic sclerosis.

Authors:  Nadera J Sweiss; Linda Hushaw; Thenappan Thenappan; Ray Sawaqed; Roberto F Machado; Amit R Patel; Mardi Gomberg-Maitland; Aliya N Husain; Stephen L Archer
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

4.  Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France.

Authors:  Alain Fraisse; Xavier Jais; Jean-Marc Schleich; Sylvie di Filippo; Pascale Maragnès; Maurice Beghetti; Virginie Gressin; Michel Voisin; Claire Dauphin; Pierre Clerson; François Godart; Damien Bonnet
Journal:  Arch Cardiovasc Dis       Date:  2010-02-11       Impact factor: 2.340

5.  Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database.

Authors:  Giorgia Martini; Ivan Foeldvari; Ricardo Russo; Ruben Cuttica; Anne Eberhard; Angelo Ravelli; Thomas J A Lehman; Sheila Knupp Feitosa de Oliveira; Gordana Susic; Galina Lyskina; Dana Nemcova; Robert Sundel; Fernanda Falcini; Herman Girschick; Ana Paula Lotito; Antonella Buoncompagni; Flavio Sztajnbok; Sulaiman M Al-Mayouf; Ilonka Orbàn; Clodoveo Ferri; Balu H Athreya; Patricia Woo; Francesco Zulian
Journal:  Arthritis Rheum       Date:  2006-12

6.  Factors affecting survival in juvenile systemic sclerosis.

Authors:  G Martini; F Vittadello; O Kasapçopur; S Magni Manzoni; F Corona; C Duarte-Salazar; D Nemcova; C A Len; S M Garay; S Ullman; F Zulian
Journal:  Rheumatology (Oxford)       Date:  2008-10-14       Impact factor: 7.580

7.  Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.

Authors:  David Langleben; Stylianos E Orfanos; Michele Giovinazzo; Andrew Hirsch; Murray Baron; Jean-Luc Senécal; Apostolos Armaganidis; John D Catravas
Journal:  Arthritis Rheum       Date:  2008-04

8.  Severe cardiac involvement in children with systemic sclerosis and myositis.

Authors:  Pierre Quartier; Damien Bonnet; Jean-Christophe Fournet; Christine Bodemer; Philippe Acar; Marie Ouachée-Chardin; Jérome Le Bidois; Anne-Marie Prieur
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

9.  Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis.

Authors:  D Mukerjee; D St George; C Knight; J Davar; A U Wells; R M Du Bois; C M Black; J G Coghlan
Journal:  Rheumatology (Oxford)       Date:  2004-01-06       Impact factor: 7.580

10.  Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia.

Authors:  Ramnath Misra; Gurmeet Singh; Parshant Aggarwal; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2006-12-19       Impact factor: 3.650

View more
  3 in total

1.  New Insights into Cardiac Involvement in Juvenile Scleroderma: A Three-Dimensional Echocardiographic Assessment Unveils Subclinical Ventricle Dysfunction.

Authors:  Reyhan Dedeoglu; Amra Adroviç; Funda Oztunç; Sezgin Sahin; Kenan Barut; Ozgur Kasapcopur
Journal:  Pediatr Cardiol       Date:  2017-09-14       Impact factor: 1.655

2.  Evaluation of six-minute walk test in juvenile systemic sclerosis.

Authors:  Oya Koker; Amra Adrovic; Sezgin Sahin; Mehmet Yildiz; Kenan Barut; Rukiye Eker Omeroglu; Ozgur Kasapcopur
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

3.  Juvenile Scleroderma: A Referral Center Experience.

Authors:  Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Arch Rheumatol       Date:  2018-01-18       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.